<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37554332</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Identification of prior dengue-na&#xef;ve Dengvaxia recipients with an increased risk for symptomatic dengue during fever surveillance in the Philippines.</ArticleTitle><Pagination><StartPage>1202055</StartPage><MedlinePgn>1202055</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1202055</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1202055</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Dengue virus (DENV) is the leading cause of mosquito-borne viral diseases in humans. Dengvaxia, the first licensed dengue vaccine, is recommended for DENV-seropositive individuals aged 9-45 years. In the Philippines, Dengvaxia was administered to more than 830,000 children without prior serological testing in 2016-2017. Subsequently, it was revealed that DENV-seronegative children who received Dengvaxia developed severe disease following breakthrough DENV infection. As a result, thousands of children participating in the mass vaccination campaign were at higher risk of severe dengue disease. It is vital that an assay that identifies baseline DENV-na&#xef;ve Dengvaxia recipients be developed and validated. This would permit more frequent and extensive assessments and timely treatment of breakthrough DENV infections.</AbstractText><AbstractText Label="METHODS">We evaluated the performance of a candidate assay, the DENV1-4 nonstructural protein 1 (NS1) IgG enzyme-linked immunosorbent assay (ELISA), developed by the University of Hawaii (UH), using well-documented serum/plasma samples including those &gt;20 years post-DENV infection, and tested samples from 199 study participants including 100 Dengvaxia recipients from the fever surveillance programs in the Philippines.</AbstractText><AbstractText Label="RESULTS">The sensitivity and specificity of the assay were 96.6% and 99.4%, respectively, which are higher than those reported for pre-vaccination screening. A significantly higher rate of symptomatic breakthrough DENV infection was found among children that were DENV-na&#xef;ve (10/23) than among those that were DENV-immune (7/53) when vaccinated with Dengvaxia (p=0.004, Fisher's exact test), demonstrating the feasibility of the assay and algorithms in clinical practice.</AbstractText><AbstractText Label="CONCLUSION">The UH DENV1-4 NS1 IgG ELISA can determine baseline DENV serostatus among Dengvaxia recipients not only during non-acute dengue but also during breakthrough DENV infection, and has implications for assessing the long-term safety and effectiveness of Dengvaxia in the post-licensure period.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Dai, Sy, Jiz, Tsai, Bato, Quino&#xf1;es, Reyes and Wang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Yu-Ching</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sy</LastName><ForeName>Ava Kristy</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>National Reference Laboratory for Dengue and Other Arboviruses, Virology Department, Research Institute for Tropical Medicine, Muntinlupa, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiz</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Immunology Department, Research Institute for Tropical Medicine, Muntinlupa, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Jih-Jin</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Tropical Medicine Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bato</LastName><ForeName>Joan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Reference Laboratory for Dengue and Other Arboviruses, Virology Department, Research Institute for Tropical Medicine, Muntinlupa, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quino&#xf1;es</LastName><ForeName>Mary Ann</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>National Reference Laboratory for Dengue and Other Arboviruses, Virology Department, Research Institute for Tropical Medicine, Muntinlupa, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reyes</LastName><ForeName>Mary Anne Joy</ForeName><Initials>MAJ</Initials><AffiliationInfo><Affiliation>National Reference Laboratory for Dengue and Other Arboviruses, Virology Department, Research Institute for Tropical Medicine, Muntinlupa, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei-Kung</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 GM114737</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI149502</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="Y">Dengue</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="Y">Dengue Virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010679" MajorTopicYN="N" Type="Geographic">Philippines</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dengvaxia</Keyword><Keyword MajorTopicYN="N">dengue virus</Keyword><Keyword MajorTopicYN="N">enzyme-linked immunosorbent assay</Keyword><Keyword MajorTopicYN="N">serostatus</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>9</Day><Hour>3</Hour><Minute>58</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37554332</ArticleId><ArticleId IdType="pmc">PMC10405517</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1202055</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guzman MG, Harris E. Dengue. Lancet (2015) 385:453&#x2013;65. doi: 10.1016/S0140-6736(14)60572-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)60572-9</ArticleId><ArticleId IdType="pubmed">25230594</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. . The global distribution and burden of dengue. Nature (2013) 496:504&#x2013;7. doi: 10.1038/nature12060</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12060</ArticleId><ArticleId IdType="pmc">PMC3651993</ArticleId><ArticleId IdType="pubmed">23563266</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. new edition. Geneva, Switzerland: (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">23762963</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB, Dans LF. Dengue infection and advances in dengue vaccines for children. Lancet Child Adolesc Health (2019) 3:734&#x2013;41. doi: 10.1016/S2352-4642(19)30205-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(19)30205-6</ArticleId><ArticleId IdType="pubmed">31378686</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilder-Smith A, Hombach J, Ferguson N, Selgelid M, O'Brien K, Vannice K, et al. . Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine. Lancet Infect Dis (2019) 19:e31&#x2013;8. doi: 10.1016/S1473-3099(18)30494-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(18)30494-8</ArticleId><ArticleId IdType="pubmed">30195995</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadinegoro SR, Arredondo-Garc&#xed;a JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. . Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med (2015) 373:1195&#x2013;206. doi: 10.1056/NEJMoa1506223</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1506223</ArticleId><ArticleId IdType="pubmed">26214039</ArticleId></ArticleIdList></Reference><Reference><Citation>Dengue vaccine WHO. WHO position paper &#x2013; July 2016. Weekly Epidemiological Rec (2016) 91:349&#x2013;64.</Citation></Reference><Reference><Citation>Halstead SB, Katzelnick LC, Russell PK, Markoff L, Aguiar M, Dans LR, et al. . Ethics of a partially effective dengue vaccine: Lessons from the Philippines. Vaccine (2020) 38:5572&#x2013;76. doi: 10.1016/j.vaccine.2020.06.079</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.06.079</ArticleId><ArticleId IdType="pmc">PMC7347470</ArticleId><ArticleId IdType="pubmed">32654899</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas SJ, Yoon IK. A review of Dengvaxia&#xae;: development to deployment. Hum Vaccin Immunother (2019) 15:2295&#x2013;314. doi: 10.1080/21645515.2019.1658503</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2019.1658503</ArticleId><ArticleId IdType="pmc">PMC6816420</ArticleId><ArticleId IdType="pubmed">31589551</ArticleId></ArticleIdList></Reference><Reference><Citation>Flasche S, Wilder-Smith A, Hombach J, Smith PG. Estimating the proportion of vaccine-induced hospitalized dengue cases among Dengvaxia vaccinees in the Philippines. Wellcome Open Res (2019) 4:165. doi: 10.12688/wellcomeopenres.15507.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/wellcomeopenres.15507.1</ArticleId><ArticleId IdType="pmc">PMC6880258</ArticleId><ArticleId IdType="pubmed">31815190</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento EJM, George JK, Velasco M, Bonaparte MI, Zheng L, DiazGranados CA, et al. . Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus. J Virol Methods (2018) 257:48&#x2013;57. doi: 10.1016/j.jviromet.2018.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2018.03.007</ArticleId><ArticleId IdType="pubmed">29567514</ArticleId></ArticleIdList></Reference><Reference><Citation>Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, et al. . Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med (2018) 379:327&#x2013;40. doi: 10.1056/NEJMoa1800820</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1800820</ArticleId><ArticleId IdType="pubmed">29897841</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Dengue vaccine: WHO position paper - September 2018. Weekly Epidemiological Rec (2018) 93:457&#x2013;76.</Citation></Reference><Reference><Citation>Wilder-Smith A, Smith PG, Luo R, Kelly-Cirino C, Curry D, Larson H, et al. . Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine: A meeting report. Vaccine (2019) 37:5137&#x2013;46. doi: 10.1016/j.vaccine.2019.07.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.07.016</ArticleId><ArticleId IdType="pubmed">31377079</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo R, Fongwen N, Kelly-Cirino C, Harris E, Wilder-Smith A, Peeling RW. Rapid diagnostic tests for determining dengue serostatus: a systematic review and key informant interviews. Clin Microbiol Infect (2019) 25:659&#x2013;66. doi: 10.1016/j.cmi.2019.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2019.01.002</ArticleId><ArticleId IdType="pmc">PMC6543064</ArticleId><ArticleId IdType="pubmed">30664935</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaparte M, Zheng L, Garg S, Guy B, Lustig Y, Schwartz E, et al. . Evaluation of rapid diagnostic tests and conventional enzyme-linked immunosorbent assays to determine prior dengue infection. J Travel Med (2019) 26(8):taz078. doi: 10.1093/jtm/taz078</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jtm/taz078</ArticleId><ArticleId IdType="pubmed">31616949</ArticleId></ArticleIdList></Reference><Reference><Citation>Limothai U, Tachaboon S, Dinhuzen J, Hunsawong T, Ong-Ajchaowlerd P, Thaisomboonsuk B, et al. . Dengue pre-vaccination screening test evaluation for the use of dengue vaccine in an endemic area. PloS One (2021) 16:e0257182. doi: 10.1371/journal.pone.0257182</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0257182</ArticleId><ArticleId IdType="pmc">PMC8432984</ArticleId><ArticleId IdType="pubmed">34507347</ArticleId></ArticleIdList></Reference><Reference><Citation>Echegaray F, Laing P, Hernandez S, Marquez S, Harris A, Laing I, et al. . Adapting rapid diagnostic tests to detect historical dengue virus infections. Front Immunol (2021) 12:703887. doi: 10.3389/fimmu.2021.703887</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.703887</ArticleId><ArticleId IdType="pmc">PMC8344047</ArticleId><ArticleId IdType="pubmed">34367162</ArticleId></ArticleIdList></Reference><Reference><Citation>DiazGranados CA, Bonaparte M, Wang H, Zhu M, Lustig Y, Schwartz E, et al. . Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials. Lancet Infect Dis (2021) 21:529&#x2013;36. doi: 10.1016/S1473-3099(20)30695-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30695-2</ArticleId><ArticleId IdType="pmc">PMC9759790</ArticleId><ArticleId IdType="pubmed">33212068</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberal V, Forrat R, Zhang C, Pan C, Bonaparte M, Yin W, et al. . Performance evaluation of a dengue IgG rapid diagnostic test designed to determine dengue serostatus as part of prevaccination screening. Microbiol Spectr (2021) 10:e0071121. doi:&#xa0;10.1128/spectrum.00711-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.00711-21</ArticleId><ArticleId IdType="pmc">PMC9241662</ArticleId><ArticleId IdType="pubmed">35604130</ArticleId></ArticleIdList></Reference><Reference><Citation>Daag JV, Ylade M, Adams C, Jadi R, Crisostomo MV, Alpay R, et al. . Evaluation of a new point-of-care test to determine prior dengue infection for potential use in pre-vaccination screening. Clin Microbiol Infect (2021) 27:904&#x2013;8. doi: 10.1016/j.cmi.2020.08.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.08.026</ArticleId><ArticleId IdType="pubmed">32866651</ArticleId></ArticleIdList></Reference><Reference><Citation>Sangkaew S, Ming D, Boonyasiri A, Honeyford K, Kalayanarooj S, Yacoub S, et al. . Risk predictors of progression to severe disease during the febrile phase of dengue: a systematic review and meta-analysis. Lancet Infect Dis (2021) 21:1014&#x2013;26. doi: 10.1016/S1473-3099(20)30601-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30601-0</ArticleId><ArticleId IdType="pmc">PMC8240557</ArticleId><ArticleId IdType="pubmed">33640077</ArticleId></ArticleIdList></Reference><Reference><Citation>Htun TP, Xiong Z, Pang J. Clinical signs and symptoms associated with WHO severe dengue classification: a systematic review and meta-analysis. Emerg Microbes Infect (2021) 10:1116&#x2013;28. doi: 10.1080/22221751.2021.1935327</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1935327</ArticleId><ArticleId IdType="pmc">PMC8205005</ArticleId><ArticleId IdType="pubmed">34036893</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan K, Chen Y, Zhong M, Lin Y, Liu L. Risk and predictive factors for severe dengue infection: A systematic review and meta-analysis. PloS One (2022) 17:e0267186. doi: 10.1371/journal.pone.0267186</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0267186</ArticleId><ArticleId IdType="pmc">PMC9012395</ArticleId><ArticleId IdType="pubmed">35427400</ArticleId></ArticleIdList></Reference><Reference><Citation>Arien KK, Wilder-Smith A. Dengue vaccine: reliably determining previous exposure. Lancet Global Health (2018) 6:e830&#x2013;1. doi: 10.1016/S2214-109X(18)30295-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(18)30295-X</ArticleId><ArticleId IdType="pubmed">29941282</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated). (Geneva, Switzerland: WHO; ) (2011).</Citation></Reference><Reference><Citation>Wichmann O, Vannice K, Asturias EJ, de Albuquerque Luna EJ, Longini I, Lopez AL, et al. . Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness. Vaccine (2017) 35:5535&#x2013;42. doi: 10.1016/j.vaccine.2017.08.066</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.08.066</ArticleId><ArticleId IdType="pubmed">28893477</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson TC, Diamond MS, Flaviviruses. Knipe DM, Howley PM. Fields virology. 6th ed. (Philadelphia: Lippincott William &amp; Wilkins; ) (2013) p. 747&#x2013;94.</Citation></Reference><Reference><Citation>Lai CY, Tsai WY, Lin SR, Kao CL, Hu SP, King CC, et al. . Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol (2008) 82:6631&#x2013;43. doi: 10.1128/JVI.00316-08</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00316-08</ArticleId><ArticleId IdType="pmc">PMC2447043</ArticleId><ArticleId IdType="pubmed">18448542</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, et al. . Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis (2008) 14:1232&#x2013;9. doi: 10.3201/eid1408.080287</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1408.080287</ArticleId><ArticleId IdType="pmc">PMC2600394</ArticleId><ArticleId IdType="pubmed">18680646</ArticleId></ArticleIdList></Reference><Reference><Citation>
Guidance for US. Laboratories Testing for Zika Virus Infection. (Atlanta, GA, USA: CDC&#x2019;s; ). (2019). Available at: http://www.cdc.gov/zika/laboratories/lab-guidance.html.</Citation></Reference><Reference><Citation>Tyson J, Tsai WY, Tsai JJ, Brites C, M&#xe4;ssg&#xe5;rd L, Youn HH, et al. . Combination of non-structural protein 1-based enzyme-linked immunosorbent assays can detect and distinguish various dengue virus and Zika virus infections. J Clin Microbiol (2019) 57:e01464&#x2013;18. doi:&#xa0;10.1128/JCM.01464-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01464-18</ArticleId><ArticleId IdType="pmc">PMC6355536</ArticleId><ArticleId IdType="pubmed">30429254</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai WY, Driesse K, Tsai JJ, Granat RS, Jenkins O, Hsieh SC, et al. . Enzyme-linked immunosorbent assays using virus-like particles containing mutations of conserved residues on envelop protein can distinguish three flavivirus infections. Emerg Microbe Infect (2020) 9:1722&#x2013;32. doi: 10.1080/22221751.2020.1797540</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1797540</ArticleId><ArticleId IdType="pmc">PMC7473235</ArticleId><ArticleId IdType="pubmed">32684139</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai JJ, Liu CK, Tsai WY, Liu LT, Tyson J, Tsai CY, et al. . Seroprevalence of dengue in two districts of Kaohsiung city after the largest dengue outbreak in Taiwan since world war II. PloS Negl Trop Dis (2018) 12:e0006879. doi: 10.1371/journal.pntd.0006879</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0006879</ArticleId><ArticleId IdType="pmc">PMC6218099</ArticleId><ArticleId IdType="pubmed">30356316</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai WY, Chen HL, Tsai JJ, Dejnirattisai W, Jumnainsong A, Mongkolsapaya J, et al. . Potent neutralizing human monoclonal antibodies preferentially target mature dengue virus particles: implication for novel strategy of dengue vaccine. J Virol (2018) 92:e00556&#x2013;18. doi: 10.1128/JVI.00556-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00556-18</ArticleId><ArticleId IdType="pmc">PMC6232466</ArticleId><ArticleId IdType="pubmed">30185598</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang WK, Chen HL, Yang CF, Hsieh SC, Juan CC, Chang SM, et al. . Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. Clin Infect Dis (2006) 243:1023&#x2013;30. doi: 10.1086/507635</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/507635</ArticleId><ArticleId IdType="pubmed">16983615</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera BB, Tsai WY, Brites C, Luz E, Pedroso C, Drexler JF, et al. . T cell responses to nonstructural protein 3 distinguish infections by dengue and Zika viruses. mBio (2018) 9:e00755&#x2013;18. doi: 10.1128/mBio.00755-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00755-18</ArticleId><ArticleId IdType="pmc">PMC6083909</ArticleId><ArticleId IdType="pubmed">30087165</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BW, Russell BJ, Lanciotti RS. Serotype-specific detection of dengue viruses in a fourplex realtime reverse transcriptase PCR assay. J Clin Microbiol (2005) 43:4977&#x2013;83. doi: 10.1128/JCM.43.10.4977-4983.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.43.10.4977-4983.2005</ArticleId><ArticleId IdType="pmc">PMC1248506</ArticleId><ArticleId IdType="pubmed">16207951</ArticleId></ArticleIdList></Reference><Reference><Citation>Biggs JR, Sy AK, Ashall J, Santoso MS, Brady OJ, Reyes MAJ, et al. . Combining rapid diagnostic tests to estimate primary and post-primary dengue immune status at the point of care. PloS Negl Trop Dis (2022) 16:e0010365. doi: 10.1371/journal.pntd.0010365</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0010365</ArticleId><ArticleId IdType="pmc">PMC9067681</ArticleId><ArticleId IdType="pubmed">35507552</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey A, Di Canzio J, Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods (1998) 221:35&#x2013;41. doi: 10.1016/S0022-1759(98)00170-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-1759(98)00170-7</ArticleId><ArticleId IdType="pubmed">9894896</ArticleId></ArticleIdList></Reference><Reference><Citation>Balmaseda A, Stettler K, Carrera RM, Collado D, Jin X, Zambrana JV, et al. . A novel antibody-based assay discriminates Zika virus infection from other flaviviruses. Proc Natl Acad Sci USA (2017) 114:8384&#x2013;9. doi: 10.1073/pnas.1704984114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1704984114</ArticleId><ArticleId IdType="pmc">PMC5547631</ArticleId><ArticleId IdType="pubmed">28716913</ArticleId></ArticleIdList></Reference><Reference><Citation>Balmaseda A, Zambrana JV, Collado D, Garc&#xed;a N, Sabor&#xed;o S, Elizondo D, et al. . Comparison of four serological methods and two reverse transcription-PCR assays for diagnosis and surveillance of Zika virus infection. J Clin Microbiol (2018) 56:e01785&#x2013;17. doi: 10.1128/JCM.01785-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01785-17</ArticleId><ArticleId IdType="pmc">PMC5824050</ArticleId><ArticleId IdType="pubmed">29305550</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev (1998) 11:480&#x2013;96. doi: 10.1128/CMR.11.3.480</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.11.3.480</ArticleId><ArticleId IdType="pmc">PMC88892</ArticleId><ArticleId IdType="pubmed">9665979</ArticleId></ArticleIdList></Reference><Reference><Citation>Busch MP, Kleinman SH, Tobler LH, Kamel HT, Norris PJ, Walsh I, et al. . Virus and antibody dynamics in acute West Nile virus infection. J Infect Dis (2008) 198:984&#x2013;93. doi: 10.1086/591467</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/591467</ArticleId><ArticleId IdType="pubmed">18729783</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu PY, Chen LK, Chang SF, Yueh YY, Chow L, Chien LJ, et al. . Comparison of capture immunoglobulin M (IgM) and IgG enzyme-linked immunosorbent assay (ELISA) and nonstructural protein NS1 serotype-specific IgG ELISA for differentiation of primary and secondary dengue virus infections. Clin Diagn Lab Immunol (2003) 10:622&#x2013;30. doi: 10.1128/CDLI.10.4.622-630.2003</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CDLI.10.4.622-630.2003</ArticleId><ArticleId IdType="pmc">PMC164246</ArticleId><ArticleId IdType="pubmed">12853395</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu PY, Chang SF, Yueh YY, Chow L, Chien LJ, Kuo YC, et al. . Current status of dengue diagnosis at the Center for Disease Control, Taiwan. Dengue Bull (2004) 28:107&#x2013;17.</Citation></Reference><Reference><Citation>
WHO . Regional Office for the Western Pacific. Dengue situation update, Dengue in Philippines. West Pacific, Manila:  (2019). Available at: https://apps.who.int/iris/handle/10665/279856.</Citation></Reference><Reference><Citation>Guzman MG, Kouri G, Valdes L, Bravo J, Vazquez S, Halstead SB. Enhanced severity of secondary dengue 2 infections occurring at an interval of 20 compared with 4 years after dengue 1 infection. PAHO J Epidemiol (2002) 81:223&#x2013;7.</Citation></Reference><Reference><Citation>Montoya M, Gresh L, Mercado JC, Williams KL, Vargas MJ, Gutierrez G, et al. . Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PloS Negl Trop Dis (2013) 7:e2357. doi: 10.1371/journal.pntd.0002357</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002357</ArticleId><ArticleId IdType="pmc">PMC3738476</ArticleId><ArticleId IdType="pubmed">23951377</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson KB, Gibbons RV, Cummings DA, Nisalak A, Green S, Libraty DH, et al. . A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis (2014) 209:360&#x2013;8. doi: 10.1093/infdis/jit436</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit436</ArticleId><ArticleId IdType="pmc">PMC3883164</ArticleId><ArticleId IdType="pubmed">23964110</ArticleId></ArticleIdList></Reference><Reference><Citation>Coudeville L, Baurin N, Vergu E. Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies. Vaccine (2016) 34:6417&#x2013;25. doi: 10.1016/j.vaccine.2015.11.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.11.023</ArticleId><ArticleId IdType="pubmed">26614588</ArticleId></ArticleIdList></Reference><Reference><Citation>Ylade M, Agrupis KA, Daag JV, Crisostomo MV, Tabuco MO, Sy AK, et al. . Effectiveness of a single-dose mass dengue vaccination in Cebu, Philippines: A case-control study. Vaccine (2021) 39:5318&#x2013;25. doi: 10.1016/j.vaccine.2021.07.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.07.042</ArticleId><ArticleId IdType="pubmed">34373121</ArticleId></ArticleIdList></Reference><Reference><Citation>Raulino R, Thaurignac G, Butel C, Villabona-Arenas CJ, Foe T, Loul S, et al. . Multiplex detection of antibodies to Chikungunya, O'nyong-nyong, Zika, Dengue, West Nile and Usutu viruses in diverse non-human primate species from Cameroon and the Democratic Republic of Congo. PloS Negl Trop Dis (2021) 15:e0009028. doi: 10.1371/journal.pntd.0009028</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0009028</ArticleId><ArticleId IdType="pmc">PMC7853492</ArticleId><ArticleId IdType="pubmed">33476338</ArticleId></ArticleIdList></Reference><Reference><Citation>Plennevaux E, Moureau A, Arredondo-Garc&#xed;a JL, Villar L, Pitisuttithum P, Tran NH, et al. . Impact of dengue vaccination on serological diagnosis: insights from phase III dengue vaccine efficacy trials. Clin Infect Dis (2018) 66:1164&#x2013;72. doi: 10.1093/cid/cix966</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cix966</ArticleId><ArticleId IdType="pmc">PMC5888923</ArticleId><ArticleId IdType="pubmed">29300876</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>